Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

146.24 -0.40 (-0.27%)
Official Closing Price Updated: 7:00 PM EST, Dec 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,176,307
Open 147.20
Bid (Size) 146.09 (1)
Ask (Size) 146.24 (9)
Prev. Close 146.64
Today's Range 146.01 - 147.77
52wk Range 143.13 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 3.39%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Johnson & Johnson
Via Business Wire
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over
Via The Motley Fool
Topics Stocks
Exposures US Equities

Performance

YTD
-8.58%
-8.58%
1 Month
-4.19%
-4.19%
3 Month
-11.18%
-11.18%
6 Month
+0.54%
+0.54%
1 Year
-6.13%
-6.13%

More News

Read More
Jim Cramer Says This CEO 'Built An Amazing Company,' Recommends Buying Netflix
Via Benzinga
Jim Cramer Bullish On Netflix Nearing $1,000 And AMD's 'Cheap' Valuation Despite Nvidia Dominance
Via Benzinga
The Analyst Landscape: 15 Takes On Johnson & Johnson
Via Benzinga
Why NYSE:JNJ is a Top Pick for Dividend Investors.
Via Chartmill
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
Via Benzinga
Elon Musk's Net Worth Surpasses Market Cap Of US Giants Like BofA, Johnson & Johnson, Salesforce, Chevron, Coca-Cola And More: Only 25 Companies Have Higher Market Cap
Via Benzinga
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
From Johnson & Johnson
Via Business Wire
Price Over Earnings Overview: Johnson & Johnson
Via Benzinga
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Via Investor's Business Daily
Coca-Cola cs. Procter & Gamble: Which Is the Better Dow Dividend King Stock to Buy Before the End of the Year?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Top Analyst Reports For Home Depot, Johnson & Johnson & Salesforce
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Celebrating innovation happens from the inside out
Via Brandpoint
Ray Dalio's Bridgewater Adds Broadcom, Apple, SMCI In Q3, While Offloading Stake In AI Giant Nvidia And Other Big Tech Companies
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
Via The Motley Fool
Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
2 Very Healthy Dividend Stocks to Hold for Decades of Income
Via The Motley Fool
3 Dividend Stocks That Are Screaming Buys in November
Via The Motley Fool
2 Unstoppable Dividend Stocks to Buy Now With $500
Via The Motley Fool
2 Dow Jones Dividend Stocks With Yields Above 3% You Can Buy Now and Hold at Least a Decade
Via The Motley Fool
Topics Stocks
Exposures US Equities
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Via MarketBeat
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.